SCHEMBL23909142

SCHEMBL23909142

CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
FNTA P49354 7/20 0.50
FNTB P49356 5/20 0.50
ALOX15 P16050 4/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.47
MEN1 O00255 2/20 0.47
CYP3A4 P08684 2/20 0.47
UGT1A1 P22309 1/20 0.47
SQLE Q14534 2/20 0.46
PGGT1B P53609 3/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310923 1.00 KMT2A (0.52) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL10297991 1.00 KMT2A (0.52) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL23887967 0.87 HPGD (0.49) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL23903835 0.87 FNTA (0.38) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL9609390 0.83 ALDH1A1 (0.38) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL23888067 0.81 LSS (0.59)
SCHEMBL3193242 0.80 ALOX15 (0.56) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL12997108 0.80 ALOX15 (0.56) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL3751814 0.80 ALOX15 (0.56) KMT2AFNTAFNTBALOX15ALDH1A1
SCHEMBL3193249 0.80 ALOX15 (0.56) KMT2AFNTAFNTBALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400588-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-05 US disclosed
US-12037350-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
US-12037350-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
CN-115996916-A Compositions and methods for preventing and/or treating mitochondrial diseases including friedreich ataxia 康德生物医疗有限公司 2023-04-21 CN disclosed
EP-4126836-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA Stealth BioTherapeutics Inc. (US) 2023-02-08 EP disclosed
US-20210317146-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037350-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia FH, COQ8A, TFAM KMT2A 2676/4885FNTA 1919/4885FNTB 1630/4885
US-20240400588-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2676/4885FNTA 1919/4885FNTB 1630/4885
US-20210317146-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2676/4885FNTA 1919/4885FNTB 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.